Robert Blum, Senior Vice President, Finance & Corporate Development and Chief Financial Officer, joined Cytokinetics at the time it commenced operations in 1998. Mr. Blum has over 20 years experience in sales, marketing, finance, business development and general management in the biotechnology and pharmaceutical industries. Prior to joining Cytokinetics, he was Director, Marketing at COR Therapeutics, where he had responsibility for readying COR for the initiation of commercial activities and was responsible for the launch in 1998 of INTEGRILIN(R) (eptifibatide), a top selling biopharmaceutical and category leader. From 1991 to 1996, he was Director, Business Development of COR Therapeutics and had responsibility for licensing, corporate partnering and strategic marketing. Prior to that, Mr. Blum worked for both Marion Laboratories and Syntex Laboratories during transactional high growth phases for each respective company in a variety of positions of increasing responsibility in sales, marketing and business planning. Mr. Blum has Bachelor degrees in both Human Biology and Economics from Stanford University and holds an M.B.A. from Harvard Business School.

Kenneth A. Clark is Managing Partner of Wilson Sonsini Goodrich & Rosati's Technology Transactions Group, which specializes in transactions involving products and/or technology, from strategic alliances to license, development, supply and distribution arrangements. He is also a member of the Firm's Executive Management Committee and Policy Committee. Ken has negotiated more than 50 major strategic alliance transactions in both the life sciences and information technology industries. He also regularly represents companies in spin-outs and core technology licenses, as well as other technology transactions. From 1992 to 1993, Ken served as Vice President, General Counsel & Secretary of Maxtor Corporation, then a $1.5 billion disk drive manufacturer. He received his undergraduate degree in 1980 from Vanderbilt University and his law degree in 1985 from the University of Texas.

Mr. Kassberg has 13 years experience in the pharmaceutical industry, including eight years at Bristol-Myers Squibb, where he held a variety of positions, including senior manager, financial planning for the U.S. Pharmaceutical Group, director of strategic planning for the Japanese affiliate company, and account director for large managed heath care customers in the U.S. In 1996, he joined SUGEN, Inc., where he assumed responsibility for licensing and business development activities. Upon the acquisition of SUGEN by Pharmacia & Upjohn in August 1999, Mr. Kassberg assumed additional responsibilities as senior director, corporate licensing, for the parent company, Pharmacia Corporation. Mr. Kassberg holds a Masters in Management degree from Northwestern University.

Dr. Linda M. Pullan is Director of Licensing at Amgen where she leads a group focused on cancer technology and product candidate in-licensing. The group works to identify, evaluate and negotiate for new opportunities and has done deals ranging from late stage clinical opportunities to enabling technologies and academic collaborations. Linda has 20 years of experience in the pharma and biotech industry, in licensing and drug discovery research at Monsanto/Searle, Zeneca Pharmaceuticals and Amgen. Her PhD is in biochemistry from the University of California and her BS in chemistry from the University of Utah.